✦ LIBER ✦

Treatment of human lung carcinoma xenografts with a combination of131I-labelled monoclonal antibody Po66 and doxorubicin

✍ Scribed by B. Desrues; F. Brichory; H. Léna; P. Bourguet; P. Delaval; L. Toujas; L. Dazord

Publisher: Springer-Verlag
Year: 1997
Tongue: English
Weight: 176 KB
Volume: 43
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s002620050333

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Advantage of yttrium-90-labeled over iod

Advantage of yttrium-90-labeled over iodine-131-labeled monoclonal antibodies in the treatment of a human lung carcinoma xenograft

✍ Rhona Stein; Susan Chen; Sara Haim; David M. Goldenberg 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 129 KB

BACKGROUND. The purpose of this investigation was to compare the therapeutic Rhona Stein, Ph

Distribution of 111in- and 125i-labeled

Distribution of 111in- and 125i-labeled monoclonal antibody 17-1a in mice bearing xenografts of human pancreatic carcinoma hup-t4

✍ Masatoshi Maeda; Miki Shoji; Toshiyuki Kawagoshi; Ryusuke Futatsuya; Takashi Hon 📂 Article 📅 1994 🏛 John Wiley and Sons 🌐 English ⚖ 732 KB

Biodistribution and pharmacokinetics of

Biodistribution and pharmacokinetics of 125I-labeled monoclonal antibody M75 specific for carbonic anhydrase IX, an intrinsic marker of hypoxia, in nude mice xenografted with human colorectal carcinoma

✍ Adrián Chrastina; Jan Závada; Seppo Parkkila; Štefan Kaluz; Milota Kaluzová; Júl 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 French ⚖ 417 KB

## Abstract Carbonic anhydrase IX (CA IX) is frequently expressed in human carcinomas and absent from the corresponding normal tissues. Strong induction by tumor hypoxia predisposes CA IX to serve as a target for cancer diagnostics and therapy. Here we evaluated targeting properties and pharmacokin

Experimental treatment of human diffuse

Experimental treatment of human diffuse large B-cell lymphoma xenografts by doxycycline alone or in combination with the anti-CD20 chimeric monoclonal antibody rituximab

✍ Franck Assayag; Nicole Brousse; Jérôme Couturier; Elizabeth Macintyre; Claire Ma 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 258 KB 👁 2 views

The addition of cisplatin to cyclophosph

The addition of cisplatin to cyclophosphamide-doxorubicin-etoposide combination chemotherapy in the treatment of patients with small cell lung carcinoma : A randomized study of 457 patients

✍ Thierry Urban; Claude Chastang; François-Xavier Lebas; Jean-Paul Duhamel; Guy Ad 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB 👁 2 views

## BACKGROUND. To assess whether the addition of cisplatin (100 mg/m 2 administered intravenously on Day 1) to CDE (cyclophosphamide [1000 mg/m 2 on Day 1], doxorubicin [45 mg/m 2 on Day 1], and etoposide [150 mg/m 2 on Days 1 and 2] combination is useful in the treatment of patients with small cel

A phase I clinical and pharmacologic stu

A phase I clinical and pharmacologic study of a carboplatin and irinotecan regimen combined with recombinant human granulocyte-colony stimulating factor in the treatment of patients with advanced nonsmall cell lung carcinoma

✍ Hiroaki Okamoto; Akira Nagatomo; Hideo Kunitoh; Hiroshi Kunikane; Koshiro Watana 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB 👁 3 views

BACKGROUND. This Phase I study was designed to determine the toxicity and efficacy of a carboplatin and irinotecan (CPT-11) regimen with recombinant human granulocyte colony-stimulating factor (rhG-CSF) support for patients with advanced nonsmall cell lung carcinoma. ## METHODS. Treatment consist